Yes - been around and have some scars to show for it :)
We may have many things we agree on regarding Nader's means, methods and ways but also disagree on some of the cause/effect of the most significant issues we have witnessed such as the BLA botch. This is not taking any accountability and responsibility from Nader but keep in mind that the FDA is not accountable to anyone (despite what you may hear about checks and balances) and gets away with ambiguity, re-direction, stall/delay and 'just one more thing - Columbo style' means to throw anything off course. I'm not insinuating its always nefarious but am stating that these things cause havoc in the timeline and stability of a filing plan.
Lastly - I think the conundrum about needing a strong and bio-fit CEO is a key element that needs examining. Wishing upon a CEO the likes of those that run any of the big pharmas (JnJ, Glaxo, Pfizer, Merck, etc.) is unrealistic as those CEOs are rarely the ones that take a company from pre-revenue to a megaorg. In addition - I would position that many of those CEOs would not know how to street fight for survival of a pre-revenue biotech as they are skilled and trained to wage strategy and wars with very large treasure chest and apply that as one of their tools. Our CEO can do much better in some aspects but I would always be in the gray on this one and that is where we may differ.
Having seen and researched the 13D slate I can tell you unequivocally, from my standpoint, there is not a single person in that group that can do a better job. And more so, they are banded together with (what seems to be the main driving force) hatred for Nader and do not coalesce around anything positive in terms of synergistic benefits or value of combined skills. That kind of binding force can bring nothing but destruction to CytoDyn as if they ever gained power (and my bet is they will not) - they would turn in on themselves in a race towards liquidation and conversion to cash. It's like season 5 of the Money Heist ;)
AI
Market Data 
Markets 
